Metastatic urothelial cancer (UC) is associated with poor prognosis. In the first-line setting,
platinum-based chemotherapy is the standard of care but resistance rapidly occurs. With no …

… of targeted therapeutic … therapies, the emerging role of putative biomarkers in predicting
response to platinum-based chemotherapy and/or immunotherapy, novel targeted therapies and …

… Four distinct subsets or expression clusters of urothelial carcinoma were identified via
integrated analyses of mRNA, miRNA, and protein data, which formed clusters I to IV. Only 3 of …

… Despite significant advances and the approval of immune checkpoint inhibitors, metastatic
urothelial carcinoma (mUC) is still very hard to treat and has poor outcomes. Deeper …

… that permit the application of targeted therapy in a series of … 20–25% of urothelial carcinomas,
and such mutations occur … several clinical trials in urothelial carcinoma, and are approved …

… targeted therapy in urothelial carcinoma. Moreover, patients usually have better health status
and a lower tumor burden in neoadjuvant setting, which may help screen large number of …

… This review describes the current landscape of targeted therapies in urothelial carcinoma.
The standard of care for advanced urothelial carcinoma patients remains platinum-based …

… Molecular targeted therapies against similar genetic … in urothelial carcinoma has not been
established. This review describes the genomic landscape of malignant urothelial carcinomas, …

… The major histologic type in western countries is urothelial carcinoma (UC), accounting for
more than 90% of all BCs. UC can also take place, but less frequently, in other parts of the …

… approved FGFR targeted therapy for urothelial carcinoma. … Consequently, multiple
FGFR-directed targeted therapies … -4, is the only approved targeted therapy in metastatic UC …